I see that alny has 2 analysts already. How does an analyst truly cover a company in preclinical development? Have they a new crystal ball regarding the outcome of experiments not yet done? At least one of them was neutral, but one outperform? Outperform what - their experiments will work better than others experiments?
RNAi looks promising. However, developing a profitable product is a long hard road as I and my colleagues in biotech are aware. Making it through clinical trials to market is a long way off in the future.
In the chemical industry the saw is "test tubes to tank cars = ten years". Biotech is longer still - how about "cell culture to syringes = seventeen years".